Takeda Pharmaceutical Company Limited
CANCER TREATMENT METHODS BASED ON TP53 MUTATION STATUS AND HYPERMUTATION STATUS

Abstract:

The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.